Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorg van Loosdregt

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Cell Genomics|January 8, 2024
A cis-regulatory element regulates ERAP2 expression through autoimmune disease risk SNPsWouter J Venema, Sanne Hiddingh, Jorg van Loosdregt, et al.
Nature Communications|May 29, 2026
Native long-read RNA sequencing of human monocytes reveals activation-induced alternative splicing toward functional isoformsAlejandra Bodelón, Maurice J H van Haaren, Paula Sobrevals Alcaraz, et al.
Nature Communications|May 12, 2021
Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammationGerdien Mijnheer, Lisanne Lutter, Michal Mokry, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2025
Impact of Interleukin-1 Blockade on the Development of Macrophage Activation Syndrome in Still Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification CriteriaRemco G A Erkens, Greta Rogani, Laura Huber, et al.
JCI Insight|June 8, 2026
LDL receptor-mediated lipoprotein uptake fuels human CD4+ T cell polarization toward a c-MAF/IL-10- and FOXP3-driven phenotypeAngela Markovska, Niels S van Heusden, Dagmar Duijzer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up StudyNienke M Ter Haar, E H Pieter van Dijkhuizen, Joost F Swart, et al.
Journal of Leukocyte Biology|April 24, 2024
N6-methyladenosine promotes TNF mRNA degradation in CD4+ T lymphocytesEllen C N van Vroonhoven, Lucas W Picavet, Rianne C Scholman, et al.
Immunity|August 27, 2013
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacityJorg van Loosdregt, Veerle Fleskens, Juan Fu, et al.
Pediatric Rheumatology Online Journal|April 8, 2021
Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritisAnouk Verwoerd, Wineke Armbrust, Katherine Cowan, et al.
Cell Reports|June 2, 2023
Pyruvate metabolism controls chromatin remodeling during CD4<sup>+</sup> T cell activationEnric Mocholi, Laura Russo, Keshav Gopal, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Cell Genomics|January 8, 2024
A cis-regulatory element regulates ERAP2 expression through autoimmune disease risk SNPsWouter J Venema, Sanne Hiddingh, Jorg van Loosdregt, et al.
Nature Communications|May 29, 2026
Native long-read RNA sequencing of human monocytes reveals activation-induced alternative splicing toward functional isoformsAlejandra Bodelón, Maurice J H van Haaren, Paula Sobrevals Alcaraz, et al.
Nature Communications|May 12, 2021
Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammationGerdien Mijnheer, Lisanne Lutter, Michal Mokry, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 27, 2025
Impact of Interleukin-1 Blockade on the Development of Macrophage Activation Syndrome in Still Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification CriteriaRemco G A Erkens, Greta Rogani, Laura Huber, et al.
JCI Insight|June 8, 2026
LDL receptor-mediated lipoprotein uptake fuels human CD4+ T cell polarization toward a c-MAF/IL-10- and FOXP3-driven phenotypeAngela Markovska, Niels S van Heusden, Dagmar Duijzer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 9, 2019
Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up StudyNienke M Ter Haar, E H Pieter van Dijkhuizen, Joost F Swart, et al.
Journal of Leukocyte Biology|April 24, 2024
N6-methyladenosine promotes TNF mRNA degradation in CD4+ T lymphocytesEllen C N van Vroonhoven, Lucas W Picavet, Rianne C Scholman, et al.
Immunity|August 27, 2013
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacityJorg van Loosdregt, Veerle Fleskens, Juan Fu, et al.
Pediatric Rheumatology Online Journal|April 8, 2021
Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritisAnouk Verwoerd, Wineke Armbrust, Katherine Cowan, et al.
Cell Reports|June 2, 2023
Pyruvate metabolism controls chromatin remodeling during CD4<sup>+</sup> T cell activationEnric Mocholi, Laura Russo, Keshav Gopal, et al.
Pageof 6